Cargando…
Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
SIMPLE SUMMARY: Few data are available for the use of (11)C-choline positron emission tomography/computed tomography (PET/CT) in patients with hepatocellular carcinoma (HCC). The aim of the study was to analyze the clinical impact of this metabolic imaging in patients with HCC candidates for hepatec...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865313/ https://www.ncbi.nlm.nih.gov/pubmed/33530520 http://dx.doi.org/10.3390/cancers13030472 |
_version_ | 1783647816982200320 |
---|---|
author | Donadon, Matteo Lopci, Egesta Galvanin, Jacopo Giudici, Simone Del Fabbro, Daniele Lanza, Ezio Pedicini, Vittorio Chiti, Arturo Torzilli, Guido |
author_facet | Donadon, Matteo Lopci, Egesta Galvanin, Jacopo Giudici, Simone Del Fabbro, Daniele Lanza, Ezio Pedicini, Vittorio Chiti, Arturo Torzilli, Guido |
author_sort | Donadon, Matteo |
collection | PubMed |
description | SIMPLE SUMMARY: Few data are available for the use of (11)C-choline positron emission tomography/computed tomography (PET/CT) in patients with hepatocellular carcinoma (HCC). The aim of the study was to analyze the clinical impact of this metabolic imaging in patients with HCC candidates for hepatectomy. Seven parameters were recorded for PET/CT in 60 patients. The Cox regression for overall survival (OS) showed that Barcelona stages (p = 0.003) and metabolic tumor volume (MTV) (p = 0.026) were the only factors independently associated with OS and furthermore, curve analysis revealed MTV ability in predicting OS. Patients with MTV ≥ 380 had worse OS (p = 0.015). The use of (11)C-choline PET/CT allows for better prognostic refinement in patients undergoing hepatectomy for HCC: integration of such metabolic modality into HCC staging system should be considered. ABSTRACT: (11)C-choline positron emission tomography/computed tomography (PET/CT) has been used for patients with some types of tumors, but few data are available for hepatocellular carcinoma (HCC). We queried our prospective database for patients with HCC staged with (11)C-choline PET/CT to assess the clinical impact of this imaging modality. Seven parameters were recorded: maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), liver standardized uptake value (SUVliver), metabolic tumor volume (MTV), photopenic area, metabolic tumor burden (MTB = MTVxSUVmean), and SUVratio (SUVmax/SUVliver). Analysis was performed to identify parameters that could be predictors of overall survival (OS). Sixty patients were analyzed: fourteen (23%) were in stage 0-A, 37 (62%) in stage B, and 9 (15%) in stage C of the Barcelona classification. The Cox regression for OS showed that Barcelona stages (HR = 2.94; 95%CI = 1.41–4.51; p = 0.003) and MTV (HR = 2.11; 95%CI = 1.51–3.45; p = 0.026) were the only factors independently associated with OS. Receiver operating characteristics curve analysis revealed MTV ability in discriminating survival (area under the curve (AUC) = 0.77; 95%CI = 0.57–097; p < 0.001: patients with MTV ≥ 380 had worse OS (p = 0.015)). The use of (11)C-choline PET/CT allows for better prognostic refinement in patients undergoing hepatectomy for HCC. Incorporation of such modality into HCC staging system should be considered. |
format | Online Article Text |
id | pubmed-7865313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78653132021-02-07 Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma Donadon, Matteo Lopci, Egesta Galvanin, Jacopo Giudici, Simone Del Fabbro, Daniele Lanza, Ezio Pedicini, Vittorio Chiti, Arturo Torzilli, Guido Cancers (Basel) Article SIMPLE SUMMARY: Few data are available for the use of (11)C-choline positron emission tomography/computed tomography (PET/CT) in patients with hepatocellular carcinoma (HCC). The aim of the study was to analyze the clinical impact of this metabolic imaging in patients with HCC candidates for hepatectomy. Seven parameters were recorded for PET/CT in 60 patients. The Cox regression for overall survival (OS) showed that Barcelona stages (p = 0.003) and metabolic tumor volume (MTV) (p = 0.026) were the only factors independently associated with OS and furthermore, curve analysis revealed MTV ability in predicting OS. Patients with MTV ≥ 380 had worse OS (p = 0.015). The use of (11)C-choline PET/CT allows for better prognostic refinement in patients undergoing hepatectomy for HCC: integration of such metabolic modality into HCC staging system should be considered. ABSTRACT: (11)C-choline positron emission tomography/computed tomography (PET/CT) has been used for patients with some types of tumors, but few data are available for hepatocellular carcinoma (HCC). We queried our prospective database for patients with HCC staged with (11)C-choline PET/CT to assess the clinical impact of this imaging modality. Seven parameters were recorded: maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), liver standardized uptake value (SUVliver), metabolic tumor volume (MTV), photopenic area, metabolic tumor burden (MTB = MTVxSUVmean), and SUVratio (SUVmax/SUVliver). Analysis was performed to identify parameters that could be predictors of overall survival (OS). Sixty patients were analyzed: fourteen (23%) were in stage 0-A, 37 (62%) in stage B, and 9 (15%) in stage C of the Barcelona classification. The Cox regression for OS showed that Barcelona stages (HR = 2.94; 95%CI = 1.41–4.51; p = 0.003) and MTV (HR = 2.11; 95%CI = 1.51–3.45; p = 0.026) were the only factors independently associated with OS. Receiver operating characteristics curve analysis revealed MTV ability in discriminating survival (area under the curve (AUC) = 0.77; 95%CI = 0.57–097; p < 0.001: patients with MTV ≥ 380 had worse OS (p = 0.015)). The use of (11)C-choline PET/CT allows for better prognostic refinement in patients undergoing hepatectomy for HCC. Incorporation of such modality into HCC staging system should be considered. MDPI 2021-01-26 /pmc/articles/PMC7865313/ /pubmed/33530520 http://dx.doi.org/10.3390/cancers13030472 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Donadon, Matteo Lopci, Egesta Galvanin, Jacopo Giudici, Simone Del Fabbro, Daniele Lanza, Ezio Pedicini, Vittorio Chiti, Arturo Torzilli, Guido Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma |
title | Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma |
title_full | Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma |
title_fullStr | Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma |
title_full_unstemmed | Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma |
title_short | Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma |
title_sort | prognostic value of metabolic imaging data of (11)c-choline pet/ct in patients undergoing hepatectomy for hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865313/ https://www.ncbi.nlm.nih.gov/pubmed/33530520 http://dx.doi.org/10.3390/cancers13030472 |
work_keys_str_mv | AT donadonmatteo prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma AT lopciegesta prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma AT galvaninjacopo prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma AT giudicisimone prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma AT delfabbrodaniele prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma AT lanzaezio prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma AT pedicinivittorio prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma AT chitiarturo prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma AT torzilliguido prognosticvalueofmetabolicimagingdataof11ccholinepetctinpatientsundergoinghepatectomyforhepatocellularcarcinoma |